Medicare Enrolled
Dr. Stavroula Otis, M.D.
Hematology & Oncology · Orange, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Otis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Otis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Otis
Dr. Stavroula Otis is a hematology & oncology specialist in Orange, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Otis performed 121,898 Medicare services across 2,060 unique beneficiaries.
Between the years covered by Open Payments, Dr. Otis received a total of $23,262 from 70 pharmaceutical and/or device companies across 990 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Otis is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 5% volume in CA
$23,262 industry payments
Medicare Practice Summary
Medicare Utilization ↗121,898
Medicare services
Top 5% in CA for hematology & oncology
2,060
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,416 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
72,750 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 25,560 | $18 | $61 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
6,081 | $6 | $21 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,421 | $6 | $21 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,518 | $0 | $0 |
| Injection, granisetron hydrochloride, 100 mcg | 1,456 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,447 | $104 | $361 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,376 | $8 | $21 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,366 | $8 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
747 | $13 | $41 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
328 | $123 | $402 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
261 | $26 | $86 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
211 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
206 | $26 | $83 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
197 | $31 | $100 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 149 | $132 | $546 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
139 | $61 | $196 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
114 | $60 | $194 |
| New patient office visit, complex (60-74 min) | 114 | $178 | $625 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
94 | $68 | $210 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
85 | $152 | $501 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
78 | $75 | $263 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
54 | $14 | $44 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
54 | $1 | $5 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
34 | $87 | $302 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $108 | $347 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
19 | $34 | $56 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
18 | $72 | $181 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
60.4% high complexity
35.7% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,262
Total received (2018-2024)
Avg $3,323/year across 7 years
Top 19% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
990
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,398 (79.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,640 (19.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$224 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,529
2023
$2,912
2022
$5,514
2021
$1,337
2020
$1,921
2019
$4,377
2018
$4,673
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$272
Novartis Pharmaceuticals Corporation
$258
Gilead Sciences, Inc.
$215
Janssen Biotech, Inc.
$201
Celgene Corporation
$194
BeiGene USA, Inc.
$127
Takeda Pharmaceuticals U.S.A., Inc.
$100
Merck Sharp & Dohme LLC
$97
E.R. Squibb & Sons, L.L.C.
$88
PFIZER INC.
$85
Incyte Corporation
$77
ABBVIE INC.
$58
ARRAY BIOPHARMA INC
$52
Rigel Pharmaceuticals, Inc.
$43
Genentech USA, Inc.
$42
AstraZeneca Pharmaceuticals LP
$41
Tolmar, Inc.
$41
PUMA BIOTECHNOLOGY, INC.
$39
Boehringer Ingelheim Pharmaceuticals, Inc.
$38
Exelixis Inc.
$37
Regeneron Healthcare Solutions, Inc.
$37
EMD Serono, Inc.
$34
Lilly USA, LLC
$34
GENZYME CORPORATION
$28
Coherus Biosciences Inc.
$27
Ipsen Biopharmaceuticals, Inc
$27
SpringWorks Therapeutics, Inc.
$26
Karyopharm Therapeutics Inc.
$26
Amneal Pharmaceuticals LLC
$25
Fennec Pharmaceuticals, Inc.
$25
MorphoSys, US Inc.
$25
Stemline Therapeutics Inc.
$22
Janssen Pharmaceuticals, Inc
$22
Astellas Pharma US Inc
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
GlaxoSmithKline, LLC.
$16
Kyowa Kirin, Inc.
$15
Top 3 companies account for 29.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$4,773
E.R. Squibb & Sons, L.L.C.
$2,011
AstraZeneca Pharmaceuticals LP
$1,786
Merck Sharp & Dohme Corporation
$1,228
PFIZER INC.
$1,143
NOVARTIS PHARMACEUTICALS CORPORATION
$1,050
Janssen Biotech, Inc.
$922
Gilead Sciences, Inc.
$823
Amgen Inc.
$684
Celgene Corporation
$638
Pharmacyclics LLC, An AbbVie Company
$602
Genentech USA, Inc.
$599
EMD Serono, Inc.
$521
Lilly USA, LLC
$431
AbbVie, Inc.
$413
Incyte Corporation
$410
BeiGene USA, Inc.
$385
Puma Biotechnology, Inc.
$366
Daiichi Sankyo Inc.
$330
Astellas Pharma US Inc
$316
Bayer HealthCare Pharmaceuticals Inc.
$282
ARRAY BIOPHARMA INC
$274
Boehringer Ingelheim Pharmaceuticals, Inc.
$272
Merck Sharp & Dohme LLC
$207
ABBVIE INC.
$185
Exelixis Inc.
$158
AbbVie Inc.
$156
GENZYME CORPORATION
$136
Teva Pharmaceuticals USA, Inc.
$121
Array BioPharma Inc.
$115
MEDIVATION FIELD SOLUTIONS LLC
$112
Takeda Pharmaceuticals U.S.A., Inc.
$100
Dendreon Pharmaceuticals LLC
$93
Seagen Inc.
$90
Foundation Medicine, Inc.
$86
Janssen Products, LP
$85
Kite Pharma, Inc.
$79
PUMA BIOTECHNOLOGY, INC.
$77
Karyopharm Therapeutics Inc.
$76
GlaxoSmithKline, LLC.
$76
Verastem, Inc.
$73
TOLMAR Pharmaceuticals, Inc.
$73
Coherus Biosciences Inc.
$70
Partner Therapeutics, Inc.
$66
Alexion Pharmaceuticals, Inc.
$58
MorphoSys, US Inc.
$50
Bayer Healthcare Pharmaceuticals Inc.
$45
Rigel Pharmaceuticals, Inc.
$43
Epizyme, Inc.,
$41
Tolmar, Inc.
$41
Regeneron Healthcare Solutions, Inc.
$37
Aveo Pharmaceuticals, Inc.
$34
Clovis Oncology, Inc.
$34
Kyowa Kirin, Inc.
$32
Eisai Inc.
$27
Ipsen Biopharmaceuticals, Inc
$27
SpringWorks Therapeutics, Inc.
$26
Amneal Pharmaceuticals LLC
$25
Fennec Pharmaceuticals, Inc.
$25
Aurobindo Pharma USA, Inc.
$25
SERVIER PHARMACEUTICALS LLC
$24
Mylan Institutional Inc.
$24
Janssen Pharmaceuticals, Inc
$23
Stemline Therapeutics Inc.
$22
Agios Pharmaceuticals, Inc.
$21
TESARO, Inc.
$20
Adaptive Biotechnologies Corporation
$20
Organon LLC
$18
EISAI INC.
$18
Cumberland Pharmaceuticals, Inc.
$14
Top 3 companies account for 36.8% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ALIMTA · AVASTIN · Abraxane · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Enhertu · Erleada · FARESTON · FASLODEX · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Folotyn · Fulphila · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Itovebi · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kaletra · Kyprolis · LEUKINE · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · Leukine · Lupron · Lupron Depot · MEKINIST · MONJUVI · MVASI · NERLYNX · NEXPLANON · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · Onivyde · PADCEV · PLUVICTO · PROMACTA · PROVENGE · Padcev · Pedmark · Perjeta · Phesgo · Polivy · Pomalyst · Poteligeo · Prolia · REBLOZYL · RUXIENCE · RYBREVANT · RYDAPT · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SOLIRIS · SUTENT · Stivarga · TAFINLAR · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (79%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
243
Per 100K population
7.7
County median income
$113,702
Nearest hospital
PROVIDENCE ST. JOSEPH HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Otis is a mixed practice specialist, with above-average Medicare volume (top 5% in CA), with low-engagement industry engagement in the top 19% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Otis experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Otis performed 72,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Otis receive payments from pharmaceutical companies?
Yes. Dr. Otis received a total of $23,262 from 70 companies across 990 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Otis's costs compare to other hematology & oncology specialists in Orange?
Dr. Otis's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Otis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Orange
Browse hematology & oncology specialists in Orange ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology